Candida Infection Testing Market Insights Highlight Segment Expansion And Market Leadership

The landscape of candida infection testing is evolving rapidly, driven by advancements in diagnostic technologies and an increasing need for fast and accurate fungal infection detection. As awareness about fungal infections grows, so does the demand for innovative testing solutions, making this market a focal point for healthcare providers and diagnostic companies alike. Let's explore the current market size, key players, emerging trends, and the main segments shaping this industry.

Projected Growth and Size of the Candida Infection Testing Market
The candida infection testing market is set to experience significant growth over the next few years. It is projected to reach a valuation of $22.56 billion by 2030, growing at a compound annual growth rate (CAGR) of 6.1%. This upward trajectory is largely fueled by a surge in demand for rapid fungal diagnostic tools, a greater uptake of molecular and microbiome testing methods, the expansion of point-of-care fungal testing, increased investments in infectious disease diagnostics, and a heightened emphasis on personalized antifungal treatments. Key market trends during this period include the widening use of molecular candida detection techniques, the rise of rapid nucleic acid amplification tests (NAAT), deeper incorporation of microbiome analysis, growth in hospital-based fungal diagnostic services, and an intensified focus on early identification of fungal infections.

The candida infection testing market size has grown strongly in recent years. It will grow from $16.72 billion in 2025 to $17.8 billion in 2026 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to increasing incidence of fungal infections, growth in immunocompromised patient populations, expansion of hospital diagnostic services, adoption of culture-based fungal testing, rising awareness of antifungal resistance.

Download a free sample of the candida infection testing market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19356&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Leading Companies Driving Innovation in the Candida Infection Testing Market
Several prominent companies dominate the candida infection testing sector, including Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Hologic Inc., bioMérieux SA, Bio-Rad Laboratories Inc., Bruker Corporation, QIAGEN N.V., Cepheid, Randox Laboratories Ltd., Meridian Bioscience Inc., DiaSorin S.p.A., Sekisui Diagnostics LLC, Enzo Biochem Inc., T2 Biosystems Inc., Aidian Oy, SafeCare LLC, CHROMagar, HK Biotek Inc., Health Testing Centers LLC, Accesa Labs LLC, and Private MD Labs LLC.

A notable development occurred in February 2024 when Bruker Corporation, a US-based scientific instruments and analytical solutions provider, finalized its acquisition of ELITechGroup for about €870 million (approximately $942 million) in cash. This strategic acquisition strengthens Bruker's position in molecular diagnostics and infectious disease testing by integrating ELITechGroup's cutting-edge technologies and expertise. ELITechGroup, headquartered in France, is recognized globally as a leader in in vitro diagnostics (IVD).

View the full candida infection testing market report:
https://www.thebusinessresearchcompany.com/report/candida-infection-testing-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Emerging Trends Shaping the Candida Infection Testing Market
Innovation is central to the market's evolution as companies focus on developing advanced diagnostic tools. Among these, fully automated PCR rapid tests for detecting candida have gained traction, offering improved accuracy and faster results. Such tests utilize polymerase chain reaction (PCR) technology to swiftly identify Candida species in patient samples.

For example, in May 2024, Bosch Healthcare Solutions GmbH, a medical technology firm based in Germany, introduced a PCR test for candida auris on its Vivalytic platform. This test provides fully automated, rapid detection in under an hour at the point of care. By delivering prompt screenings, it significantly outperforms traditional culture methods that take one to three days in centralized labs, thus expediting diagnosis and treatment. Tailored for clinical environments, this innovation is especially critical for high-risk patients, enabling timely intervention against the serious health threats posed by C. auris infections.

Detailed Segmentation Analysis of the Candida Infection Testing Market
The candida infection testing market is categorized into several key segments:

1) By Type:
- Invasive Candidiasis
- Candidemia

2) By Test Type:
- Vaginal pH Test
- Nucleic Acid Amplification Testing (NAAT)
- Microbiome Test

3) By Application:
- Hospital
- Laboratory

Further breakdowns include:

Within Invasive Candidiasis:
- Tissue Biopsy Testing
- Urine Culture Testing
- Blood Culture Testing

Within Candidemia:
- Blood Tests
- Serological Testing
- Molecular Testing

These segments offer a comprehensive view of the market, highlighting the variety of testing methods and applications that cater to different clinical needs and settings.

What's included in our 2026 market reports:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 30,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.